2
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Conditions
Keratosis, Actinic
7
Neoplasms
5
Melanoma
3
Warts
2
Prostatic Neoplasms
2
Neoplasm Metastasis
2
Hyperthermia
2
Hematologic Neoplasms
2
Hemangioma
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Tuberous Sclerosis
1
Squamous Intraepithelial Lesions
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors Harboring NTRK Fusion
1
Small Cell Lung Carcinoma
1
Skin Neoplasms
1
Seizures
1
Sarcoma
1
Recurrence
1
Rectal Neoplasms
1
Polycystic Ovary Syndrome
1
Pituitary Neoplasms
1
Pelvic Neoplasms
1
Pain
1
Ovarian Neoplasms
1
Obesity
1
Nonmelanoma Skin Cancers
1
Mucositis
1
Interventions
Cisplatin
55
Carboplatin
50
pembrolizumab
42
Paclitaxel
42
Gemcitabine
28
Pemetrexed
23
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
Solutions
×
Clear all
NCT06022757
2024-02-23
KEYNOTE F19
Evopoint Biosciences Inc.
Phase 1/2
Recruiting
204 enrolled